Pharmacokinetics of natural human IFN-α in hemodialysis patients

Journal of Interferon and Cytokine Research

Volumn 19, Issue 10, 1999, Pages 1117-1123

  Gotoh, Akinobu ^a   Hara, Isao ^a   Fujisawa, Masato ^a   Okada, Hiroshi ^a   Arakawa, Souichi ^a   Kudo, Shoji ^b   Obe, Toru ^c   Maruyama, Satoshi ^d   Sakai, Rumi ^e   Kamidono, Sadao ^a  

^a KOBE UNIVERSITY   (Japan)

^b OTSUKA PHARMACEUTICAL CO LTD   (Japan)

^c Akashi Municipal Hospital   (Japan)

^d Takasago Municipal Hospital   (Japan)

^e Sumiyoshigawa Hospital   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON;

ARTICLE; CASE REPORT; CYTOKINE PRODUCTION; HEMODIALYSIS; HUMAN; KIDNEY CLEARANCE; KIDNEY FUNCTION; PRIORITY JOURNAL;

AGED; ANTIVIRAL AGENTS; CARCINOMA, RENAL CELL; CASE-CONTROL STUDIES; FEMALE; HUMANS; INJECTIONS, INTRAMUSCULAR; INTERFERON-ALPHA; KIDNEY NEOPLASMS; MALE; MIDDLE AGED; RENAL DIALYSIS;

EID: 0032742090     PISSN: 10799907     EISSN: None     Source Type: Journal    
DOI: 10.1089/107999099313055     Document Type: Article

References (41)

1. BOCCI, V., PACINI, A., MUSCETTOLA, M., PAULESU, L., and PESSINA, G.P. (1981). Renal metabolism of rabbit serum Interferon. J. Gen. Virol. 55, 297-304.
2. BOCCI, V., PACINI, A., MUSCETTOLA, M., PAULESU, L., PESSINA, G.P., SANTIANO, M., and VIANO, I. (1981). Renal filtration, absorption and catabolism of human alpha interferon. J. Interferon Res. 1, 347-352.
3. BOCCI, V., PACINI, A., MUSCETTOLA, M., PESSINA, G.P., PAULESU, L., and BANDINELLI, L. (1982). The kidney is the main site of interferon catabolism. J. Interferon Res. 2, 309-314.
4. BINO, T., EDERY, H., GERTLER, A., and ROSENBERG, H. (1982). Involvement of the kidney in catabolism of human leukocyte interferon. J. Gen. Virol. 59, 39-45.
5. BINO, T., MADAR, Z., GERTLER, A., and ROSENBERG, H. (1982). The kidney is the main site of interferon degradation. J. Interferon Res. 2, 301-308.
6. TOKAZEWSKI-CHEN, S.A., MARAFINO, B.J., Jr., and STEBBING, N. (1983). Effects of nephrectomy on the pharmacokinetics of various cloned human interferons in the rat. J. Pharmacol. Exp. Ther. 227, 9-15.
7. 125I-interferon alpha in lysosomes of rabbit proximal tubule cells. J. Submicrosc. Cytol. 16, 753-757.
8. 125I]-labeled human leukocyte-derived alpha interferon in the rat. J. Interferon Res. 5, 121-127.
9. BOCCI, V., PACINI, A., BANDINELLI, L., PESSINA, G.P., MUSCETTOLA, M., and PAULESU, L. (1982). The role of liver in the catabolism of human α- and β-interferon. J. Gen. Virol. 60, 397-400.
10. 125I-interferon alpha by isolated perfused rabbit kidney and liver. J. Lab. Clin. Med. 101, 857-863.
11. CASANOVAS-TALTAVULL, T., BALIELLAS, C., SESÉ, E., IBORRA, M.J., BENASCO, C., ANDRÉS, E., GONZÁLEZ, M.T., GIL-VERNET, S., CASANOVA, A., and CASAIS, L.A. (1995). Interferon may be useful in hemodialysis patients with hepatitis C virus chronic infection who are candidates for kidney transplant. Transplant. Proc. 27, 2229-2230.
12. OKUDA, K., HAYASHI, H., YOKOZEKI, K., KONDO, T., KASHIMA, T., and IRIE, Y. (1995). Interferon treatment for chronic hepatitis C in haemodialysis patients: suggestions based on a small series. J. Gastroenterol. Hepatol. 10, 616-620.
13. RAPTOPOULOU-GIGI, M., SPAIA, S., GARIFALLOS, A., XENOU, P., ORPHANOU, H., ZARAFIDOU, E., PETRIDOU, P., VRETTOU, H., VAGIONAS, G., GALAKTIDOU, G., MAVROUDI, L., EFKARPIDOU, A., and KORTSARIS, A. (1995). Interferon-α2b treatment of chronic hepatitis C in haemodialysis patients. Nephrol. Dial. Transplant 10, 1834-1837.
14. FABRIZI, F., LUNGHI, G., GUARNORI, I., RAFFAELE, L., ERBA, G., PAGANO, A., and LOCATELLI, F. (1996). Hepatitis C virus genotypes in chronic dialysis patients. Nephrol. Dial. Transplant. 11, 679-683.
15. MARCELLIN, P., BOYER, N., BEHAMOU, J.-P., and ERLINGER, S. (1996). Interferon-α therapy for chronic hepatitis C in special patient populations. Dig. Dis. Sci. 41 (Suppl. 12), 126S-130S.
16. POL, S., THIERS, V., CARNOT, F., ZINS, B., ROMÉO, R., BERTHELOT, P., and BRÉCHOT, C. (1996). Effectiveness and tolerance of interferon-α2b in the treatment of chronic hepatitis C in haemodialysis patients. Nephrol. Dial. Transplant. 11 (Suppl. 4), 58-61.
17. SIMSEK, H. (1996). Interferon-alpha treatment of haemodialysis patients with chronic viral hepatitis and its impact on kidney transplantation. Nephrol. Dial. Transplant. 11, 912-913.
18. FERNÁNDEZ, J.L., RENDO, P., DEL PINO, N., NEPHROLOGISTS' GROUP FOR THE STUDY OF HCV INFECTION, and VIOLA, L. (1997). A double-blind controlled trial of recombinant interferon-α2b in haemodialysis patients with chronic hepatitis C virus infection and abnormal aminotransferase levels. J. Viral Hepat. 4, 113-119.
19. CHAN, T.M., WU, P.C., LAU, J.Y.M., LOK, A.S.F., LAI, C.L., and CHENG, I.K.P. (1997). Interferon treatment for hepatitis C virus infection in patients on haemodialysis. Nephrol. Dial. Transplant. 12, 1414-1419.
20. UMLAUFT, F., WONG, D.T., UNDERHILL, P.A., OEFNER, P.J., JIN, L., URBANEK, M., GRUENEWALD, K., and GREENBERG, H.B. (1997). Hepatitis G virus infection in hemodialysis patients and the effects of interferon treatment. Am. J. Gastroenterol. 92, 1986-1991.
21. HIRSCH, M.S., TOLKOFF-RUBIN, N.E., KELLY, A.P., and RUBIN, R.H. (1983). Pharmacokinetics of human and recombinant leukocyte interferon in patients with chronic renal failure who are undergoing hemodialysis. J. Infect. Dis. 148, 335.
22. GRIMBERT, P., DERAY, G., LEBON, P., FAUCHER, C., MALINGRE, P., RAYMOND, F., PETITCLERC, T., and JACOBS, C. (1995). Pharmacokinetics of recombinant leukocyte interferon in a patient on continuous ambulatory peritoneal dialysis. Am. J. Nephrol. 15, 175.
23. HANROTEL, C., LAVAUD, S., TOUPANCE, O., LEBON, P., and CHANARD, J. (1997). Dialysis technique modulates alpha interferon pharmacokinetics in a patient with chronic hepatitis C. Nephrol. Dial. Transplant. 12, 2804-2805.
24. KOHASE, M., KOHNO, S., YAMAZAKI, S., SHISHIDO, A., and KONO, R. (1982). Potency standardization of human interferon preparations for clinical trials. In: The Clinical Potential of Interferons. R. Kono and J. Vilcek (eds.) Tokyo, Japan: University of Tokyo Press, pp. 299-309.
25. YAMAZAKI, S. (1986). Interferon assay and its related problems. Pharma Medica 4, 111-118.
26. ANDO, S., SANOU, O., FUJII, M., SATO, Y., and KURIMOTO, M. (1987). Large-scale production and characterization of natural human interferon-α from HVJ-stimulated BALL-1 cells. Chem. Express 2, 45-48.
27. FUKUDA, S., ANDO, S., SANOU, O., TANIAI, M., FUJII, M., MASAKI, N., NAKAMURA, K., ANDO, O., TORIGOE, K., SUGIMOTO, T., and KURIMOTO, M. (1988). Simultaneous production of natural human tumor necrosis factor-α, -β and interferon-α from BALL-1 cells stimulated by HVJ. Lymphokine Res. 7, 175-185.
28. MATSUYAMA, H., YAMAMOTO, M., YOSHIHIRO, S., OHMOTO, Y., and NAITO, K. (1997). Efficacy of continuous subcutaneous infusion therapy using interferon α and the possible prognostic indicator of TNF-α in renal cell carcinoma. Int. J. Urol. 4, 447-450.
29. KINOUCHI, T., SAIKI, S., MAEDA, O., KURODA, M., USAMI, M., and KOTAKE, T. (1997). Treatment of advanced renal cell carcinoma with a combination of human lymphoblastoid interferon-α and cimetidine. J. Urol. 157, 1604-1607.
30. ICHIDA, F., SAKUMA, A., KAMIMURA, T., MATSUSHIMA, T., MAKINO, I., YACHI, A., SATO, S., IINO, S., FUJISAWA, K., SUZUKI, H., FURUTA, S., SASAKI, H., MIZOKAMI, M., SUZUKI, S., OKANOUE, T., KUROKI, T., TSUJII, T., TSUJI, T., HIRAYAMA, C., OKITA, K., NISHIOKA, M., OHTA, Y., OKUMURA, M., and TANIKAWA, K. (1991). Antiviral effect of human interferon-α (BALL-1) on patients with HBe antigen positive chronic hepatitis: a phase III study. KAN-TAN-SUI 22, 979-1000.
31. KASAHARA, A., HAYASHI, N., HIRAMATSU, N., OSHITA, M., HAGIWARA, H., KATAYAMA, K., KATO, M., MASUZAWA, M., YOSHIHARA, H., KISHIDA, Y., SHIMIZU, Y., INOUE, A., FUSAMOTO, H., and KAMADA, T. (1995). Ability of prolonged interferon treatment to suppress relapse after cessation of therapy in patients with chronic hepatitis C: a multicenter randomized controlled trial. Hepatology 21, 291-297.
32. YAMADA, G., TAKATANI, M., KISHI, F., TAKAHASHI, M., DOI, T., TSUJI, T., SHIN, S., TANNO, M., URDEA, M.S., and KOLBERG, J.A. (1995). Efficacy of interferon alfa therapy in chronic hepatitis C patients depends primarily on hepatitis C virus RNA level. Hepatology 22, 1351-1354.
33. TAKEUCHI, J., KAWAMURA, M., SAWADA, U., OHSHIMA, T., HORIE, T., HORIKOSHI, A., and ABE, T. (1995). Natural interferon α for chronic myelogenous leukemia in the chronic phase: hematologic, cytogenetic and molecular response. Jpn. J. Clin. Hematol. 36, 1149-1156.
34. KITAMURA, K., MIZOGUCHI, H., KAMATA, N., ABE, T., SAKURAI, M., TOGAWA, A., and TAKAKU, F. (1995). Hematological and genetical effects of interferon-alpha on chronic myelogenous leukemia: a multicenter phase II clinical study. Biotherapy 9, 506-528.
35. KISHIDA, T. (1994). Phase I study of OPC-18 (natural IFN-α): subcutaneous administration versus intramuscular administration. KISO TO RINSHO 28, 3539-3545.
36. ROSTAING, L., CHATELUT, E., PAYEN, J.-L., IZOPET, J., THALAMAS, C., TON-THAT, H., PASCAL, J.-P., DURAND, D., and CANAL, P. (1998). Pharmacokinetics of αIFN-2b in chronic hepatitis C virus patients undergoing chronic hemodialysis or with normal renal function: clinical implications. J. Am. Soc. Nephrol. 9, 2344-2348.
37. MAKING, I., AKIYAMA, K., and KUDO, S. (1996). Pharmacokinetics of interferon α in patients with chronic hepatitis C after repetitive intramuscular administration of natural human interferon α. KISO TO RINSHO 30, 95-101.
38. GUTTERMAN, J.U., FINE, S., QUESADA, J., HORNING, S.J., LEVINE, J.F., ALEXANIAN, R., BERNHARDT, L., KRAMER, M., SPIEGEL, H., COLBURN, W., TROWN, P., MERIGAN, T., and DZIEWANOWSKI, Z. (1982). Recombinant leukocyte A Interferon: pharraacokinetics, single-dose, tolerance, and biologic effects in cancer patients. Ann. Intern. Med. 96, 549-556.
39. RADWANSKI, E., PERENTESIS, G., JACOBS, S., ODEN, E., AFFRIME, M., SYMCHOWICZ, S., and ZAMPAGLIONE, N. (1987). Pharmacokinetics of interferon α-2b in healthy volunteers. J. Clin. Pharmacol. 27, 432-435.
40. WILLS, R.J. (1990). Clinical pharmacokinetics of interferons. Clin. Pharmacokinet. 19, 390-399.
41. TANNO, H., FERNÁNDEZ, J.L., RENDO, P., DEL PINO, N., VIOLA, L., TERG, R., and PÉREZ, V. (1995). Hepatitis C virus RNA and long-term response to recombinant interferon-α 2b in patients with chronic hepatitis C. J. Viral Hepat. 2, 97-102.